Study Purpose: The ASPIRE trial is testing a new drug called buloxibutid for people with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). This disease causes scarring in the lungs, making it hard to breathe. The study will explore if buloxibutid helps improve lung function and is safe for patients.

Key Points:

• The study lasts 52 weeks with a few visits for testing and check-ups.
• Participants will be randomly assigned to receive either buloxibutid or a placebo (a pill that looks like the medicine but has no active drug).
• Participants cannot take another drug called pirfenidone during the study.

Participation: To join, you must be 40 years or older, have been diagnosed with IPF recently, and be able to do lung tests. You should not have any other serious health problems or be pregnant. The study hopes to enroll up to 270 participants. All participants need to agree to the study rules and sign a consent form before starting.

For more details, visit the ASPIRE trial website.